Germantown, MD (PRWEB) August 15, 2012
SupplementsToWeightLoss LLC (DBA: PharmaCo Labs) The announcement from PharmaCo Labs follows the recent online publication of a study by Katherine M. Sharkey, M.D., Ph.D. and Lifespan health system which will be published in a future print edition of the journal Sleep and Breathing. Dr. Sharkey is a member of the department of medicine, division of pulmonary, critical care and sleep medicine at Rhode Island Hospital as well as holding an academic appointment at The Warren Alpert Medical School of Brown University.
The study evaluated more than 250 patients who were preparing to undergo bariatric surgery. The patients were evaluated for obstructive sleep apnea, which is a risk factor for a number of negative health outcomes following bariatric surgery, including coronary artery disease, congestive heart failure, hypertension, stroke, and various post-operative respiratory complications as well as increasing perioperative morbidity and mortality.
Common symptoms of obstructive sleep apnea include daytime sleepiness, loss of interest and motivation, poor concentration, and poor memory. According to Dr. Sharkey, “While the vast majority of patients considering bariatric surgery for treatment of obesity have clinically significant OSA, they report fewer symptoms, and may be attributing daytime napping and decreased functioning to something other than a sleep disorder."
In addition to increasing the metabolism of dieters, which helps them to lose weight, PhenObestin 37.5 - phentermine alternative, also stimulates the central nervous system and increases the overall level of brain activity, which helps dieters to feel sharp and alert. This helps to counteract the symptoms of obstructive sleep apnea, while the weight loss may help to eventually eliminate the obstructive sleep apnea.
PhenObestin 37.5 also contains Phenylethylamine, the “feel good” compound in chocolate which boosts dopamine levels in the brain. This helps to reduce diet-inspired mood swings and depression. Another ingredient in PhenObestin 37.5 is derived from the acacia blackbush plant. This compound boosts the metabolism, burning fat, and helping to flush toxins from the body. The final compound comes from Yohimbe bark extract, and is responsible for increasing the effectiveness of the other compounds, as well as helping them to travel throughout the body so that they can reach stubborn belly and visceral fat and melt it away.
Used in the United Kingdom, United States, and Australia since 2009, PhenObestin 37.5 allows dieters to lose not just weight but fat quickly and easily, and without any side effects. It is an all-natural weight loss pill composed entirely of ingredients with known scientific pedigrees. These pharmaceutical-grade ingredients are combined in an Indianapolis-based laboratory that has been certified cGMP-FDA compliant.
For more information, contact Georgiy Kharchenko at 800-935-6312.